Clinical Trial Update: Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, efficacy and pharmacokinetics of universal CLL1-targeted CAR-T cells in relapsed/refractory acute myeloid leukemia. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Universal CLL1 CAR-T (CAR-T cell therapy targeting CLL1 (CLEC12A) antigen)

Snippet

Sponsor: Mingfeng Zhao | Conditions: Acute Myeloid Leukemia, Chimeric Antigen Receptor T-cell | Phase 1 | Status: NOT_YET_RECRUITING